Remember when Dr. Li-Meng Yan made that ominous warning about intelligence suggesting the CCP could potentially use the Winter Olympics as a vector for a hemorrhagic fever virus bioweapon?
Join The True Defender Telegram Chanel Here: https://t.me/TheTrueDefender
According to Dr. Yan, “there is already a cure for this alleged bioweapon and the CCP wants to limit its availability as much as possible. It is a Johnson & Johnson drug called Darzalex (daratumumab). According to Cancer.org, the drug is currently used to treat multiple myeloma, but Dr. Yan said the CCP discovered it is also effective against their new bioweapons.”
A biopharmaceutical company called Bio-Rad has reportedly developed antibodies that inhibit daratumumab from binding to receptors in the body and stopping infection with hemorrhagic fever.
Bio-Rad's anti-daratumumab antibodies are well characterized, with ELISA protocols to help get you started with development of your anti-drug assays. https://t.co/RnawSIhxvw pic.twitter.com/fUJGttPoWd
— Bio-Rad Flow Cytometry and Antibodies (@BioRadFlowAbs) January 20, 2022
Need anti-daratumumab antibodies for anti-drug assays? Bio-Rad's recombinant, non-animal-derived, sequence defined antibodies undergo stringent quality control and provide you with security of supply. https://t.co/EyZSCpk3cb pic.twitter.com/p56eLBLVK7
— Bio-Rad Flow Cytometry and Antibodies (@BioRadFlowAbs) January 12, 2022
This will be an important article in a couple months.
Bio-Rad Introduces Anti-Daratumumab Antibodies https://t.co/n5BssMcgmu
— TheClockworkElf (@JoeRogansElf) February 15, 2022
“Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of a range of anti-daratumumab antibodies that are specific for daratumumab (Darzalex) and inhibit the binding of the drug to its target, CD38. These highly specific and high-affinity recombinant antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars,” the journal The Scientist wrote in their scientific report.
What do you think about this, now?
Isn’t it suspicious that Bio-Rad would announce antibodies that inhibit the binding ability of the drug that, according to Dr. Li-Meng Yan, easily treats hemorrhagic fever?